Blinatumomab for relapsed/refractory Burkitt's lymphoma

Dr Johannes Düll speaks to ecancer at the 2019 European Hematology Association (EHA) Annual Meeting about using blinatumomab for relapsed/refractory Burkitt's lymphoma.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.phps